文献速递糖尿病

新发心房颤动与2型糖尿病患者心血管疾病、慢性肾脏病及死亡风险的关联

Associations of New-Onset Atrial Fibrillation With Risks of Cardiovascular Disease, Chronic Kidney Disease, and Mortality Among Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2022-01-01

研究纳入英国生物银行16551例无心血管疾病和慢性肾脏病的2型糖尿病成人,随访中位10.7-11.0年,发现新发心房颤动者后续动脉粥样硬化性心血管疾病、心力衰竭、慢性肾脏病及全因和心血管死亡风险均显著升高,数据强调预防心房颤动以减少大血管和微血管并发症的重要性。

要点

  • 在2型糖尿病患者中,新发心房颤动与动脉粥样硬化性心血管疾病风险升高相关(HR 1.85)。
  • 新发心房颤动与心力衰竭风险升高相关(HR 4.40)。
  • 新发心房颤动与慢性肾脏病、全因死亡及心血管死亡风险升高相关。

核心结论

  • 发生心房颤动的2型糖尿病患者后续不良心血管事件、慢性肾脏病和死亡风险显著增加。
  • 数据强调预防心房颤动的策略对减少2型糖尿病患者大血管和微血管并发症的重要性。

研究设计与样本

  • 研究纳入英国生物银行中16551例招募时无心血管疾病和慢性肾脏病的2型糖尿病成人。
  • 采用时变Cox回归模型评估新发心房颤动与后续事件风险的关联。

主要发现

  • 随访期间1394例发生心房颤动,15157例未发生心房颤动。
  • 中位随访10.7-11.0年,记录动脉粥样硬化性心血管疾病2872例、心力衰竭852例、慢性肾脏病1548例、全因死亡1776例(中心血管死亡409例)。
  • 与未发生心房颤动者相比,新发心房颤动者动脉粥样硬化性心血管疾病风险更高(HR 1.85;95%CI 1.59-2.16)。
  • 与未发生心房颤动者相比,新发心房颤动者心力衰竭风险更高(HR 4.40;95%CI 3.67-5.28)。
  • 与未发生心房颤动者相比,新发心房颤动者慢性肾脏病风险更高(HR 1.68;95%CI 1.41-2.01),全因死亡风险更高(HR 2.91;95%CI 2.53-3.34),心血管死亡风险更高(HR 3.75;95%CI 2.93-4.80)。

关键数值与推荐

  • 新发心房颤动与动脉粥样硬化性心血管疾病的HR为1.85(95%CI 1.59-2.16)。
  • 新发心房颤动与心力衰竭的HR为4.40(95%CI 3.67-5.28)。
  • 新发心房颤动与慢性肾脏病的HR为1.68(95%CI 1.41-2.01)。
  • 新发心房颤动与全因死亡的HR为2.91(95%CI 2.53-3.34),与心血管死亡的HR为3.75(95%CI 2.93-4.80)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Atrial fibrillation (AF) frequently occurs in patients with type 2 diabetes (T2D); however, the longitudinal associations of new-onset AF with risks of adverse health outcomes in patients with T2D remain unclear. In this study, we aimed to determine the associations of new-onset AF with subsequent risks of atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and mortality among patients with T2D. RESEARCH DESIGN AND METHODS: We included 16,551 adults with T2D, who were free of cardiovascular disease (CVD) and CKD at recruitment from the UK Biobank study. Time-varying Cox regression models were used to assess the associations of incident AF with subsequent risks of incident ASCVD, heart failure, CKD, and mortality. RESULTS: Among the patients with T2D, 1,394 developed AF and 15,157 remained free of AF during the follow-up. Over median follow-up of 10.7-11.0 years, we documented 2,872 cases of ASCVD, 852 heart failure, and 1,548 CKD and 1,776 total death (409 CVD deaths). Among patients with T2D, those with incident AF had higher risk of ASCVD (hazard ratio [HR] 1.85; 95% CI 1.59-2.16), heart failure (HR 4.40; 95% CI 3.67-5.28), CKD (HR 1.68; 95% CI 1.41-2.01), all-cause mortality (HR 2.91; 95% CI 2.53-3.34), and CVD mortality (HR 3.75; 95% CI 2.93-4.80) compared with those without incident AF. CONCLUSIONS: Patients with T2D who developed AF had significantly increased risks of developing subsequent adverse cardiovascular events, CKD, and mortality. Our data underscore the importance of strategies of AF prevention to reduce macro- and microvascular complications in patients with T2D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Geng T, Wang Y, Lu Q, et al. Associations of New-Onset Atrial Fibrillation With Risks of Cardiovascular Disease, Chronic Kidney Disease, and Mortality Among Patients With Type 2 Diabetes. Diabetes Care. 2022. PMID: 35984477. doi:10.2337/dc22-0717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。